← Back to Calendar

Protagonist Therapeutics Q1 2026 Earnings

Protagonist Therapeutics · $PTGX
Standard Review Earnings
Catalyst Date
May 8, 2026
Time Remaining
25 days
Review Type
Standard (10 mo)

Live Company Data NGM

Updated 3m ago · Data: FMP
Current Price
$98.82 +141.67%
+$57.93 today
Day: $98.40 – $104.28
Market Cap
N/A
Shares out: 63.81M
Float: 51.94M
52-Week Range
$41.28
$107.84
Current price is at 86% of 52-week range
Avg Volume
784K
Beta
2.11
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $PTGX catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + rusfertide REVIVE Phase 3 data update

Key Notes

Q1 2026 earnings call expected ~May 8, 2026. Key update on rusfertide REVIVE Phase 3 trial in polycythemia vera — topline data expected H2 2026. Will confirm or adjust timeline.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar